Relapsed/Refractory Multiple Myeloma(MM)
Oncology·MeSH: Multiple Myeloma
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Unknown(1)
Frequently asked questions
How many drugs are in development for Relapsed/Refractory Multiple Myeloma(MM)?
BioSniper tracks 1 drug in development for Relapsed/Refractory Multiple Myeloma(MM) across 1 company.
How many clinical trials target Relapsed/Refractory Multiple Myeloma(MM)?
There are 1 clinical trial targeting Relapsed/Refractory Multiple Myeloma(MM) tracked by BioSniper.
What is the prevalence of Relapsed/Refractory Multiple Myeloma(MM)?
The estimated prevalence of Relapsed/Refractory Multiple Myeloma(MM) is approximately 17.0 per 100,000 population.
Deep-dive into Relapsed/Refractory Multiple Myeloma(MM)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis